EC approves Merck’s Keytruda for locally advanced, metastatic urothelial carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Commission approved Merck’s Keytruda (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login